
    
      This study will enroll haploidentical HSCT patients with high risk for acute GVHD.
      Tocilizumab (8mg/kg) will be added to the conventional acute GVHD prophylaxis regime
      (CsA+Methotrexate(MTX)+low dose mycophenolate mofetil(MMF)+ATG) on day -1 of transplant. The
      previous patients will be used as control.
    
  